High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study

Autor: Federica Barzi, Kerin O'Dea, George Jerums, Graham R D Jones, Paul D. Lawton, Elif I Ekinci, Ashim Sinha, Mark Thomas, Wendy E. Hoy, Richard J MacIsaac, Elizabeth L M Barr, Louise J. Maple-Brown, Jaquelyne T. Hughes, Alan Cass, Alex Brown
Přispěvatelé: Barr, Elizabeth LM, Barzi, Federica, Hughes, Jaquelyne T, Jerums, George, Hoy, Wendy E, O'Dea, Kerin, Jones, Graham RD, Lawton, Paul D, Brown, Alex DH, Thomas, Mark, Ekinci, Elif I, Sinha, Ashim, Cass, Alan, MacIsaac, Richard J, Maple-Brown, Louise J
Rok vydání: 2018
Předmět:
Male
Endocrinology
Diabetes and Metabolism

medicine.medical_treatment
030232 urology & nephrology
markers
population
030204 cardiovascular system & hematology
chemistry.chemical_compound
0302 clinical medicine
Medicine
Diabetic Nephropathies
Longitudinal Studies
risk
predict
function decline
Hazard ratio
Middle Aged
Renal Replacement Therapy
Receptors
Tumor Necrosis Factor
Type I

Disease Progression
nephropathy
Female
Kidney Diseases
medicine.symptom
Glomerular Filtration Rate
Adult
medicine.medical_specialty
Renal function
Nephropathy
03 medical and health sciences
Population Groups
Internal medicine
Diabetes mellitus
Internal Medicine
Albuminuria
Humans
Renal replacement therapy
Aged
Advanced and Specialized Nursing
Creatinine
business.industry
Australia
biomarkers
esrd
medicine.disease
Diabetes Mellitus
Type 2

chemistry
inflammation
ckd
business
Follow-Up Studies
Kidney disease
Zdroj: Diabetes Care. 41:739-747
ISSN: 1935-5548
0149-5992
Popis: OBJECTIVE To examine the association between soluble tumor necrosis factor receptor 1 (sTNFR1) levels and kidney disease progression in Indigenous Australians at high risk of kidney disease. RESEARCH DESIGN AND METHODS This longitudinal observational study examined participants aged ≥18 years recruited from >20 sites across diabetes and/or kidney function strata. Baseline measures included sTNFR1, serum creatinine, urine albumin-to-creatinine ratio (uACR), HbA1c, C-reactive protein (CRP), waist-to-hip ratio, systolic blood pressure, and medical history. Linear regression was used to estimate annual change in estimated glomerular filtration rate (eGFR) for increasing sTNFR1, and Cox proportional hazards were used to estimate the hazard ratio (HR) and 95% CI for developing a combined renal outcome (first of a ≥30% decline in eGFR with a follow-up eGFR RESULTS Over a median of 3 years, participants with diabetes (n = 194) in the highest compared with the lowest quartile of sTNFR1 experienced significantly greater eGFR decline (−4.22 mL/min/1.73 m2/year [95% CI −7.06 to −1.38]; P = 0.004), independent of baseline age, sex, eGFR, and uACR. The adjusted HR (95% CI) for participants with diabetes per doubling of sTNFR1 for the combined renal outcome (n = 32) was 3.8 (1.1–12.8; P = 0.03). No association between sTNFR1 and either renal outcome was observed for those without diabetes (n = 259). CONCLUSIONS sTNFR1 is associated with greater kidney disease progression independent of albuminuria and eGFR in Indigenous Australians with diabetes. Further research is required to assess whether TNFR1 operates independently of other metabolic factors associated with kidney disease progression.
Databáze: OpenAIRE